InsiderTrades

Form 4 for ACAD ACADIA PHARMACEUTICALS INC

Accepted 2024-03-27 00:00:00 ET · period of report 2024-03-25 · accession 0001415889-24-009270 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-03-27 2024-03-25 ACAD Schneyer Mark C. EVP, CFO A - Grant $0.00 +10.6K 31.6K +50% $0
D 2024-03-27 2024-03-27 ACAD Schneyer Mark C. EVP, CFO S - Sale $17.90 -5,434 26.2K -17% -$97.3K
DM 2024-03-27 2024-03-25 ACAD Schneyer Mark C. EVP, CFO A - Grant $0.00 +105.3K 80.6K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-03-25 A A 10,550 $0.00 31,617 D — — (F1) Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at 50% of target
2 Common Common Stock 2024-03-27 S D 5,434 $17.90 26,183 D — —
3 Derivative Restricted Stock Units 2024-03-25 A A 24,714 $0.00 24,714 D — · — to — 24,714 Common Stock (F4) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F5) The restricted stock units vest in four equal annual installments beginning March 25, 2025.
4 Derivative Stock Options (Right to Buy) 2024-03-25 A A 80,564 $0.00 80,564 D $17.84 · — to 2034-03-24 80,564 Common Stock (F3) 25% of the shares subject to the Stock Option will vest and become exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.